Clinical trials
Full profile accessFollow clinical development from study design and recruitment through results.
- Trial phase
- Status
- Readouts
Drug intelligence / Profile preview
davutamig
- Development stage
- Phase 2
- Lead developer
- Regeneron Pharmaceuticals
- Modality
- Bispecific Antibodies → Multispecific Antibodies → Engineered Antibody Formats → Antibody-Based Therapeutics
- Administration
- Intravenous
01
Overview
Davutamig is a bispecific human IgG4-kappa antibody designed to target and inhibit the MET receptor (c-Met, hepatocyte growth factor receptor) at two different non-overlapping epitopes. Its primary mechanism is inhibition of the MET signaling pathway, which is frequently dysregulated in certain cancers. Davutamig is being developed for the treatment of non-small cell lung cancer (NSCLC) with MET genetic alterations (including MET exon 14 skipping mutations, MET amplification, or high MET protein expression). It is an investigational antineoplastic immunotherapy agent, administered by intravenous infusion, currently in Phase 1/2 clinical trials for MET-altered NSCLC.
- Brand names
- davutamig
- Other names
- REGN5093REGN-5093REGN 5093METXMET
02
Targets
MET (Mesenchymal-epithelial transition factor receptor)
Beyond the preview
Go deeper on davutamig.
Explore the evidence, development activity, and competitive landscape with Gosset’s full data platform.
Indications & development
Full profile accessExplore development by indication, patient population, and geography.
- Indications
- Development status
- Countries
Licensing & deals
Full profile accessTrace asset ownership, licensing agreements, and commercial partnerships.
- Partners
- Deal terms
- Milestones
Patents & exclusivity
Full profile accessExplore the patent landscape and regulatory exclusivity around an asset.
- Patents
- Expiration dates
- Exclusivity
Competitive landscape
Full profile accessCompare development programs by target, modality, and indication.
- Competing assets
- Targets
- Development stage
Research & analysis
Full profile accessConnect source evidence and development news to your research questions.
- Publications
- News
- Analysis
Bring the full picture into focus.
See how Gosset can support your research on davutamig.